New Patent Battleground: Inter Partes Reviews Besiege Innovators
Executive Summary
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.
You may also be interested in...
Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal
House IP Subcommittee Chair Issa suggests legislation may address sovereign immunity and ways to make inter partes review process more palatable to patent owners.
Novartis Exelon Patch Patent Battle: PTAB Can Disagree With District Court
Federal Circuit rejects Novartis argument that Patent Trial and Appeal Board unlawfully concluded Exelon patents were unpatentable after a district court upheld them.
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.